Viatris Inc. (VTRS) Stock

Viatris Inc. (VTRS) is a Healthcare stock trading at $16.31 (as of 2026-08-21), with a market capitalization of $18.99B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Viatris Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines across multiple segments, including Developed Markets, Greater China, JANZ, and Emerging Markets. It provides brand and generic drugs, complex generics, biosimilars, and APIs for a range of therapeutic areas, selling to wholesalers, retailers, payers, insurers, governments, and institutions.

Understand Viatris Inc.: how it makes money

Viatris sells prescription brand drugs, generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs), earning revenue primarily from sales of these medicines across therapeutic areas.

Viatris' profit model is structurally driven by whether new product and biosimilar launches (tracked as new product revenue) can add enough sales to offset revenue headwinds (tracked as indoor impact) while maintaining operating cost discipline.

Business quality (Weak): For the period ended 2026-03-31, Viatris reported gross margin of 32.9% but an operating margin of -2.3%, indicating that costs and/or other operating items are overwhelming gross profit. The company is also emphasizing new product revenue, which may be important for future operating leverage.

Bull case

  • New products contribute meaningful quarterly sales: New product revenue added (quarter) was 0.14 USD_B.
  • Biosimilars are a tangible part of the product mix: Biosimilars revenue (Q1) was 0.17 USD_B.

Bear case

  • Operating profitability is currently negative: Operating margin is -2.3% for the period ended 2026-03-31.
  • Revenue headwinds are present: Indoor impact (revenue headwind) was 0.16 USD_B.
Valuation — source: SEC EDGAR (first-party)
Price$16.31
Market Cap$18.99B
EV / EBITDA10.7
Price / Book1.30
Price / Sales1.30
FCF Yield9.4%
DCF Value (model)$27.41
DCF Upside vs Price68.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$14.30B
Net Margin-24.6%
Revenue Growth (YoY)8.1%
EPS Growth (YoY)-105.9%
FCF Growth (YoY)-29.3%
Financial Health — source: SEC EDGAR
Altman Z-Score0.72 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($1.72B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOScott Andrew Smith
Employees32,000
CountryUS
IPO Date1980-03-17

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Organon & Co. (OGN)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Alnylam Pharmaceuticals, Inc. (ALNY)
  • Zoetis Inc. (ZTS)
  • United Therapeutics Corporation (UTHR)
  • Amneal Pharmaceuticals, Inc. (AMRX)
  • Royalty Pharma plc (RPRX)
  • Sarepta Therapeutics, Inc. (SRPT)
VTRS earnings history · VTRS institutional & insider holders · VTRS KPIs & operating metrics · VTRS financials · VTRS investor presentations & press releases · VTRS SEC filings · VTRS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.